Hybrid Immunoglobulins TRIZ Cases

Dual binding to CD28 and a T-cell antigen localizes costimulation near tumors, improving activation while avoiding systemic overstimulation.

Domain crossovers and targeted CH1, CL, and CH3 changes reduce heavy-light chain mispairing and improve desired antibody yield.

A dual TNFR2 and 4-1BB antibody boosts CD8+ T cells and NK cells while limiting Treg proliferation to strengthen anti-tumor immunity.

Blocking CD47-SIRPα with an antigen-binding polypeptide restores macrophage phagocytosis of tumor cells while limiting anemia risk.

Dual PD-1 and CTLA-4 targeting improves vulvar tumor treatment efficacy while lowering toxicity and reducing lymphatic metastasis.

Optimized CDR sequences and yeast surface display improve SLeA antibody affinity and glycan selectivity for cancer targeting.

Dual TL1A and TNF-α binding in one antibody format broadens inflammatory pathway inhibition for more durable IBD treatment responses.

IL-10 or IL-4 treatment suppresses monocyte-driven proinflammatory cytokines to reduce BiTE and CAR-T cytokine release syndrome.

Bispecific binders link extracellular viruses or toxins to cell surface receptors for endocytosis and lysosomal degradation, improving clearance.

Prebuilt Techneins redirect approved antibodies to new targets without structural changes, cutting response time for emerging threats.

Variant Fc domains drive stable heterodimeric antibodies that enable monovalent co-target binding, reducing nonspecific activation and toxicity.

Defined CDR monoclonal antibodies enable a sandwich immunoassay that detects adenovirus rapidly, simply, and with higher sensitivity.

Selective CH1 deletion in mouse IgG preserves functional IgM while enabling heavy chain antibodies with non-camelid VH domains.

Broadly neutralizing gp120 CD4-site antibodies such as N6 overcome resistant HIV-1 strains while maintaining potent low-IC50 activity.

Amino acid changes at heavy-light chain interfaces help kappa and lambda Fab regions pair correctly, improving bispecific antibody yield.

pH- and ion-responsive antigen-binding molecules improve FcRn recycling and Fcγ uptake to lower plasma antigen levels with less antibody.

Conditional DR4 activation through FAPα binding improves tumor-cell apoptosis while limiting liver toxicity and off-target effects.

Engineered BCMA-binding formats use Fc domains and modular linkers to preserve tumor targeting while lowering cytokine release risk.

Dextran sulfate in mammalian cell culture prevents protease clipping of Fc-FGF21 fusion proteins, improving homogeneity and stability.

High-affinity anti-IL-1β antibodies block IL-1R1 binding and downstream signaling to improve specificity and efficacy in IL-1β-driven disease treatment.

A bispecific CD3-PDL1 fusion protein redirects T-cells to PDL1+ tumors while blocking PD1-mediated immune suppression.

Fc-modified anti-PD-1/VEGFA bispecific antibodies curb ADCC and CDC damage to immune cells while blocking angiogenesis and immunosuppression.

A protease-cleavable linker enables correct light chain pairing in multispecific antibodies while avoiding extensive Fab interface changes.

A conserved-epitope CYP1A1 antibody enables cross-vertebrate exposure detection while avoiding separate species-specific assay development.

Human Vλ and Jλ segments inserted at the rodent Igκ locus expand antibody diversity and improve antigen binding specificity.

Transferrin receptor uptake and pH- or enzyme-cleavable linkers help adalimumab scFv cross brain, eye, and tumor barriers for release inside cells.

A stable linker chemistry keeps the anti-LIV-1 antibody-drug conjugate intact in serum, reducing drug detachment and toxicity.

Site-specific integration into expression-enhancing loci stabilizes multispecific antibody expression, raises titers, and limits recombination.

Fc-equipped CLDN6 bispecific antibodies extend blood half-life and stability while preserving T-cell cytotoxicity against cancer cells.

Fc-region mutations that reduce Fcγ receptor binding extend bispecific antibody half-life while lowering cytokine storm risk in cancer therapy.

By bridging BCMA on tumor cells and CD3 on T cells, these bispecific antibodies enable targeted killing of BCMA-expressing cancers.

A VHH-masked IL-2 Fc fusion stays inactive systemically, then is protease-cleaved in tumors to extend half-life and limit toxicity.

Targets Galectin-9 on regulatory T lymphocytes to block suppressor activity while preserving effector T-cell function in cancer treatment.

A humanized anti-PD-L1 nanobody Fc fusion improves binding affinity while lowering immunogenicity to block PD-L1/PD-1 and inhibit tumor growth.

A single bispecific protein blocks both TGFβ and PD-L1 signaling to boost T cell activation where single-pathway cancer therapies fall short.

An Fc-linked G-CSF complex uses a non-peptidyl polymer to extend blood stability and serum concentration with less frequent dosing.

A single ISVD construct targets IL-13 and OX40L to broaden inflammatory disease coverage while avoiding separate biologic co-administration.

Dual binding to CD28 on T cells and PSMA on tumor cells localizes costimulation, boosting anti-tumor activity while limiting peripheral toxicity.

A bispecific antibody degrader links EGFR to an internalizing receptor, enabling selective lysosomal removal of cell surface proteins.

Blocking the HHLA2-KIR3DL3 inhibitory pathway preserves HHLA2 activation signaling and can improve T and NK cell responses in resistant cancers.

A four-chain cross-over domain architecture creates three antigen binding sites to expand multi-target therapy without losing specificity.

Using an insulin receptor Fab carrier, HIR-Fab-IDS helps enzyme therapy cross the blood-brain barrier and restore lysosomal function in MPS II.

Nonpeptidyl linkers using alkyne, tetrazine, or transcyclooctene chemistry improve hybrid immunoglobulin flexibility while limiting immunogenicity.

A single bispecific protein targets PD-1 and CTLA-4 to improve cancer immune response while reducing toxicity versus combination therapy.

A common light-chain polypeptide pairs with different heavy chains to avoid mispairing and simplify bispecific antibody construction.

Site-specific integration at an expression-enhancing locus stabilizes multi-chain antibody expression and supports consistent bispecific heterodimer production.

By targeting GPRC5D, BCMA, and CD3 in one molecule, this case shows how T-cell engagement can limit antigen-loss tumor escape and recurrence.

Tuned translation initiation sequences balance antibody chain expression in eukaryotic cells, raising correctly assembled bispecific yield and purity.

High-affinity antibodies targeting tetranectin block HMGB1 interaction to reduce immunosuppression, tissue injury, and sepsis mortality.

Multimerized IL-15/IL-15Rα-Fc complexes boost T-cell and NK-cell expansion, persistence, and cytotoxicity with lower toxicity than IL-2.